logo
  

AstraZeneca: FDA Grants Priority Review For Imfinzi - Quick Facts

AstraZeneca plc (AZN.L,AZN) announced the US FDA has accepted a supplemental Biologics License Application and granted Priority Review for Imfinzi for the treatment of patients with previously untreated extensive-stage small cell lung cancer. The sBLA was based on positive results from the Phase III CASPIAN trial. The PDUFA date is set for the first quarter of 2020.

Imfinzi is approved in the curative-intent setting of unresectable, Stage III non-small cell lung cancer after chemoradiation therapy in 54 countries, including the US, Japan and the EU.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Brooklyn, New York -based Golden Natural Products, Inc. is recalling two dried apricot products as they contain undeclared sulfites, the U.S. Food and Drug Administration said. The recall involves Dried Apricot Subkhon with Bone and Dried Apricot Subkhon Jumbo. Pfizer and Moderna have raised the prices of their respective Covid vaccines for European Union, the Financial Times reported. Pharmaceutical giants renegotiated their covid vaccine supply contract with the EU citing global inflation, supply chain bottleneck and a high demand for the vaccines. A similar price hike is expected in other markets. Shares of HSBC Holdings Plc were gaining in London and Hong Kong trading after the Asia-focused lender reported Monday that its first-half profit more than doubled, despite weak revenues. Looking ahead, the company said while uncertainties remain, the outlook is more positive with evidence of growth in strategic areas.
Follow RTT